Compare AADX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AADX | ICUI |
|---|---|---|
| Founded | N/A | 1984 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2026 | 1995 |
| Metric | AADX | ICUI |
|---|---|---|
| Price | $18.60 | $161.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $169.00 |
| AVG Volume (30 Days) | ★ 1.1M | 278.8K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.20 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.46 |
| P/E Ratio | ★ N/A | $131.79 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.28 | $107.02 |
| 52 Week High | $24.24 | $162.18 |
| Indicator | AADX | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 65.01 |
| Support Level | $17.77 | $140.69 |
| Resistance Level | $24.24 | N/A |
| Average True Range (ATR) | 1.68 | 5.22 |
| MACD | -0.40 | 0.30 |
| Stochastic Oscillator | 9.02 | 91.16 |
Applied Aerospace & Defense Inc specializes in providing engineering and vertically integrated manufacturing solutions for space and defense technology companies. The company builds complex hardware for extreme operating environments, combining deep material science and IP-enabled process expertise with the ability to enable rapid prototyping, enhance new product development, and responsively scale production. The majority of the company's revenue is derived from the sales of Defense Aviation and Airborne Systems, followed by Space and Launch Systems, C5ISR and Precision Strike Systems.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.